Cox Edward, Faria Rita, Saramago Pedro, Haralambos Kate, Watson Melanie, Humphries Steve E, Qureshi Nadeem, Woods Beth
Centre for Health Economics, University of York, UK, YO10 5DD; Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK, NG7 2RD.
Centre for Health Economics, University of York, UK, YO10 5DD.
J Clin Lipidol. 2024 Nov-Dec;18(6):e1046-e1054. doi: 10.1016/j.jacl.2024.08.007. Epub 2024 Sep 4.
Familial hypercholesterolemia (FH) is a monogenic disorder that causes high levels of low-density lipoprotein (LDL) cholesterol. Cascade testing, where relatives of known individuals with FH ('index') are genetically tested, is effective and cost-effective, but implementation in the UK varies.
This study aims to provide evidence on current UK FH cascade yields and to identify common obstacles cascade services face and individual- and service-level predictors of success.
Electronic health records from 875 index families and 5,958 linked relatives in the UK's Welsh and Wessex FH services (2019) were used to explore causes for non-testing and to estimate testing rates, detection yields, and how relative characteristics and contact methods relate to the probability of relatives being tested (using logistic regression).
In Wales (Wessex), families included 7.35 (7.01) members on average, with 2.41 (1.66) relatives tested and 1.35 (0.96) diagnosed with FH per index. Cascade testing is limited by individualized circumstances (too young, not at-risk, etc.) and FH services' reach, with approximately one in four relatives out-of-area. In Wales, first-degree relatives (odds ratio (OR): 1.55 [95% confidence interval (CI): 1.28, 1.88]) and directly contacted relatives (OR: 2.11 [CI: 1.66, 2.69]) were more likely to be tested. In Wales and Wessex, women were more likely to be tested than men (ORs: 1.53 [CI: 1.28, 1.85] and 1.74 [CI: 1.32, 2.27]).
In Wales and Wessex less than a third of relatives of an index are tested for FH. Improvements are likely possible by integrating geographically dispersed families into cascade testing, services directly contacting relatives where possible, and finding new ways to encourage participation, particularly amongst men.
家族性高胆固醇血症(FH)是一种导致低密度脂蛋白(LDL)胆固醇水平升高的单基因疾病。级联检测是对已知FH患者(“索引病例”)的亲属进行基因检测,这种方法有效且具有成本效益,但在英国的实施情况各不相同。
本研究旨在提供有关英国当前FH级联检测产出的证据,并确定级联检测服务面临的常见障碍以及成功的个体和服务层面预测因素。
使用来自英国威尔士和韦塞克斯FH服务机构(2019年)的875个索引病例家庭和5958名相关亲属的电子健康记录,以探究未进行检测的原因,并估计检测率、检出率,以及亲属特征和联系方法与亲属接受检测概率之间的关系(使用逻辑回归)。
在威尔士(韦塞克斯),每个索引病例家庭平均有7.35(7.01)名成员,有2.41(1.66)名亲属接受检测,其中1.35(0.96)名被诊断为FH。级联检测受到个体情况(年龄太小、无风险等)和FH服务覆盖范围的限制,约四分之一的亲属不在服务区域内。在威尔士,一级亲属(优势比(OR):1.55 [95%置信区间(CI):1.28,1.88])和直接联系的亲属(OR:2.11 [CI:1.66,2.69])接受检测的可能性更大。在威尔士和韦塞克斯,女性接受检测的可能性高于男性(OR分别为:1.53 [CI:1.28,1.85]和1.74 [CI:1.32,2.27])。
在威尔士和韦塞克斯,不到三分之一的索引病例亲属接受了FH检测。通过将地理上分散的家庭纳入级联检测、服务机构尽可能直接联系亲属以及寻找鼓励参与的新方法,特别是在男性中,可能会有所改善。